Annexon: Unforced Error Sullies Prospects [Seeking Alpha]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Seeking Alpha
ANX005 has the potential to become the first FDA approved therapy for Guillain-Barré syndrome (GBS). GBS is a rare disease that affects patients in different ways. This is my first report on Annexon, Inc. ( NASDAQ: ANNX ) a clinical stage biotech. Annexon is on the cusp of delivering top line data on its pivotal trial of its lead therapy in development, ANX005. It strives to be the first FDA approved therapy for Guillain-Barré syndrome [GBS]. In this article I assess its prospects. I point to a decision during its development that clouds and complicates its chances of FDA approval. Sources for this article include the following released in conjunction with its Q4, 2023 earnings on 03/26/2024 — press release (the " Release ") and 10-K (the " 10-K "); I also refer to its latest 03/2024 website presentation (the " Presentation GBS syndrome is a rare disease that has terrible impact on certain patients. Presentation slide 13 lists important GBS metrics, illustrating the horri
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) [Yahoo! Finance]Yahoo! Finance
- Annexon, Inc. (NASDAQ: ANNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Are Medical Stocks Lagging Annexon (ANNX) This Year? [Yahoo! Finance]Yahoo! Finance
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.MarketBeat
ANNX
Earnings
- 3/26/24 - Beat
ANNX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- ANNX's page on the SEC website